Drug Development Pharma - November 14, 2014
AZ Developing Blood-Thinner Antidote
While sales of AstraZeneca’s blood-thinner Brilinta have been growing, the company has started a preclinical development program on a potential Brilinta antidote, now known as MEDI2452. If it works, the antidote could quickly reverse the effects of the blood thinner in an emergency, such as a person having a major bleeding episode. Doctors would not […]